Dienogest compared with gonadotropin‐releasing hormone agonist after conservative surgery for endometriosis

Yotaro Takaesu, Hirotaka Nishi, Junya Kojima, Toru Sasaki, Yuzo Nagamitsu, Rina Kato, Keiichi Isaka
Journal of Obstetrics and Gynaecology Research · 2016 · vol. 42(9) , pp. 1152–1158 · doi:10.1111/jog.13023 · PMID:27225336 · W2398997144
article OA: closed CC0 ⤵ 51 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study found dienogest improved recurrence rates compared to no treatment, with fewer side effects than goserelin, making it a useful prolonged postoperative therapy for endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

AIM: Although there are various hormone therapies, including gonadotropin-releasing hormone agonist, danazol, levonorgestrel-releasing intrauterine system, dienogest, and low-dose estrogen progestin, no consensus opinion has been reached in terms of which medication should be used and for how long it should be administered. We aimed to determine whether dienogest or goserelin is the better postoperative therapy to prevent recurrence of endometriosis. METHODS: A prospective cohort randomized study were conducted, including 198 patients diagnosed as having endometriosis. A total of 111 patients were randomly assigned into two groups: the dienogest-administered group (n = 56) and the goserelin-administered group (n = 55). Patients were followed for 24 months after laparoscopic surgery. Those who gave consent but desired no postoperative therapy were assigned to the non-treatment group (n = 79). Recurrence, side-effects, degrees of menstrual pain and chronic pelvic pain measured by the Visual Analogue Scale were compared among the three groups: the dienogest, goserelin, and non-treatment groups. RESULTS: No significant difference was observed in the postoperative recurrence rate between the dienogest and goserelin groups. No significant difference was found in the recurrence rate between the goserelin group and non-treatment group; however, a significant difference was found in the recurrence rate between the dienogest group and the non-treatment group (P = 0.027). Menstrual pain and chronic pelvic pain were significantly improved in both treatment groups. Side-effects were markedly observed in the goserelin group as compared with the dienogest group. CONCLUSION: Dienogest is available for prolonged administration of more than 6 months, so it is more useful than goserelin, which is available only for short-term administration.

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosischronic_pelvic_pain

MeSH descriptors

Conservative Treatment Endometriosis Gonadotropin-Releasing Hormone Hormone Antagonists Nandrolone Postoperative Care Adult Conservative Treatment Endometriosis Endometriosis Endometriosis Female Gonadotropin-Releasing Hormone Goserelin Goserelin Goserelin Hormone Antagonists Humans Nandrolone Nandrolone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (25)

Cited by (50)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:21:00.404924+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK